Vegenics Licenses VEGF-C Development Rights From HGS Spinoff CoGenesys
This article was originally published in The Pink Sheet Daily
Vegenics is in “leading position” in developing VEGF-C antagonists, firm says.
You may also be interested in...
Israeli generics maker pays $400 million for the biopharma, which brings an advanced drug development platform called Albumin Fusion.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee